VIVUS INC
VIVUS INC (VVUS): 6 pipeline candidates · ~17 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
17.1 months
D/E -3.92 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for VIVUS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$32.9M
Quarterly Burn
$9.2M
Runway
17.1 mo
Revenue
$19.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in VIVUS INC's pipeline?
VIVUS INC (VVUS) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is VIVUS INC's lead drug candidate?
VIVUS INC's most advanced tracked candidate is bicnu (Phase 2) for Lymphoma.
What is VIVUS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, VIVUS INC has approximately 17.1 months of cash runway.
Get the full picture on VIVUS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.